

Subject Line: Do you have COPD or emphysema?



ACRC NETWORK
Airways Clinical Research Centers



At the American Lung Association, we are committed to advancing research in respiratory care. That is why we're contacting you to inform you about a clinical trial — the Losartan Effect on Emphysema Progression (LEEP) trial. The study is funded by the American Lung Association and the National Heart, Lung, and Blood Institute.

Below please find some additional information and frequently asked questions about the study.

About the study

Results from early studies suggest that losartan, a drug commonly used for many years to treat high blood pressure, may slow damage to the lungs caused by emphysema related to COPD. This study will compare losartan and a placebo in people with emphysema. We will use high resolution computed tomography scans (HRCT scans) to see if losartan slows the progression of emphysema.

How does the study work?

Individuals who are eligible for the study and agree to join will be randomly assigned to receive Losartan or placebo for one year. Patients will receive HRCT scans at the beginning and end of the study. People who enroll will need to go to the study site every three months (for one year) for clinical examinations to monitor for side effects.

Has losartan been recalled by the FDA because of contamination?

Yes, several batches of losartan (and similar drugs) have been recalled because of contamination with a suspected carcinogen, nitrosamine compounds. Elevated levels of nitrosamines are associated with an increased risk of cancer. The losartan used for this trial has not been recalled. The study drug has been tested and meets FDA safety standards for nitrosamines.

Does it cost anything to enroll?

There is no cost to enroll in the study. Losartan or placebo will be provided by the study free of charge. Study participants will be paid for their time and will not be charged for study visits or clinical examinations.

How do I know if I am eligible to enroll in the study?

You may be eligible for the LEEP study if you are 40 years of age or older, are a current or former smoker with COPD, and live within a reasonable distance from a participating center. To see the full list of participating centers visit the American Lung Association website at <http://www.lung.org/our-initiatives/research/clinical-trials/studies/LEEP.html>.



Other ways to learn about research studies enrolling patients with COPD?

Please also consider enrolling in the COPD Patient-Powered Research Network (COPD PPRN), which is a community of individuals who want to revolutionize COPD research. The COPD PPRN is a research registry of individuals with COPD who have agreed to share their health information and the impact the disease has on their lives. The PPRN is operated and governed by members of the COPD community, including patients, community stakeholders, medical professionals, and family members. The COPD PPRN seeks to close the gap in COPD research and to provide support, knowledge sharing, and crucial resources to those with COPD. www.copdpprn.org

If you have any questions, please contact the American Lung Association at 1-800-LUNGUSA and select option 2.
Sincerely,

The American Lung Association